Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Incyte has moved up recently on speculation they'll be moving into the drug making business. The recent clinical drug failures of HGSI's KGF-2 trials is an example of the downside risk of this strategy. Of course HGSI still has a market cap that is 3-4 x Incyte's.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.